January 2, 2012 – Commencement of Autism / Fluoxetine Subpopulation Analysis

Posted by on Jan 2, 2012 in Press Release | 0 comments

Autism Therapeutics announced today that it has commenced an analysis using Personalized Pharmaceutical Systems’ proprietary technology to identify specific subpopulations within the Autism Spectrum Disorders (ASD) population that either have a higher likelihood of exhibiting a positive response to fluoxetine compared to the ASD population as a whole, or have a higher likelihood of exhibiting a placebo response. Upon completion, AT intends to seek approval from FDA to implement a novel clinical trial design for a Phase III clinical trial which targets or excludes a specific autism subpopulation.

AT Press Release January 2 2012 (Commencement of Subpopulation Analysis)